1. MS Minority Research Engagement Partnership Network. Summary of barriers to research participation for minority individuals with MS 2017. https://www.pcori.org/sites/default/files/MS-Minority-Research-Engagement-Partnership-Barriers-to-Participation.pdf. Accessed 14 Oct, 2019.
2. Khan O, Williams MJ, Amezcua L, Javed A, Larsen KE, Smrtka JM. Multiple sclerosis in US minority populations: clinical practice insights. Neurol Clin Pract. 2015;5(2):132–42.
3. TECFIDERA. TECFIDERA® (dimethyl fumarate) delayed-release capsules, for oral use. Highlights of prescribing information, Cambridge, MA, USA: Biogen; 2017. https://www.tecfidera.com/content/dam/commercial/tecfidera/pat/en_us/pdf/full-prescribing-info.pdf. Accessed 15 Oct, 2018.
4. US Food and Drug Administration. VUMERITY™ (diroximel fumarate) delayed-release capsules, for oral use. Highlights of prescribing information Cambridge, MA, USA: Biogen; 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211855s000lbl.pdf. Accessed 10 Sep, 2019.
5. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–97.